SEC Filings
Corbus Reports No Serious Psychiatric Events In Early Obesity-Pill Trial
Adverse events caused 12.9% of the highest-dose group to stop treatment; previously reported weight loss averaged 5% at 12 weeks.
Corbus Pharmaceuticals (CRBP) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Adverse events caused 12.9% of the highest-dose group to stop treatment; previously reported weight loss averaged 5% at 12 weeks.
SEC Filings
Corbus is advancing a late-stage cancer trial alongside an early-stage obesity drug study.
SEC Filings
A $15 million licensing milestone drove most of the increase in quarterly expenses, while obesity data are due November 15.
SEC Filings
The October presentation shows a head and neck cancer study as under way and lists a first-half 2028 interim response readout.